Members of the killer cell immunoglobulin-like receptor (KIR) family, a large group of polymorphic receptors expressed on natural killer (NK) cells, recognize particular peptide-laden human leukocyte antigen (pHLA) class I molecules and have a pivotal role in innate immune responses 1 . Allelic variation and extensive polymorphism within the three-domain KIR family (KIR3D, domains D0-D1-D2) affects pHLA binding specificity and is linked to the control of viral replication and the treatment outcome of certain haematological malignancies [1] [2] [3] . Here we describe the structure of a human KIR3DL1 receptor bound to HLA-B*5701 complexed with a self-peptide. KIR3DL1 clamped around the carboxy-terminal end of the HLA-B*5701 antigen-binding cleft, resulting in two discontinuous footprints on the pHLA. First, the D0 domain, a distinguishing feature of the KIR3D family, extended towards b2-microglobulin and abutted a region of the HLA molecule with limited polymorphism, thereby acting as an 'innate HLA sensor' domain. Second, whereas the D2-HLA-B*5701 interface exhibited a high degree of complementarity, the D1-pHLA-B*5701 contacts were suboptimal and accommodated a degree of sequence variation both within the peptide and the polymorphic region of the HLA molecule. Although the twodomain KIR (KIR2D) and KIR3DL1 docked similarly onto HLA-C 4,5 and HLA-B respectively, the corresponding D1-mediated interactions differed markedly, thereby providing insight into the specificity of KIR3DL1 for discrete HLA-A and HLA-B allotypes. Collectively, in association with extensive mutagenesis studies at the KIR3DL1-pHLA-B*5701 interface, we provide a framework for understanding the intricate interplay between peptide variability, KIR3D and HLA polymorphism in determining the specificity requirements of this essential innate interaction that is conserved across primate species.
HLA-B57 carriage has been associated with delayed progression to AIDS in HIV-infected individuals, with a strong genetic association between the KIR3DL1-HLA-B57 interaction, reduced viral loads and delayed HIV disease progression 3 . We expressed KIR3DL1*001, a prototypical family member, and co-complexed it with HLA-B*5701 bound to a self-peptide (LSSPVTKSF). The affinity (K D ) of this interaction was approximately 17 mM (Supplementary Table 1 and Supplementary Fig. 1 ). We then determined the KIR3DL1*001-HLA-B*5701-LSSPVTKSF structure to 1.8 Å resolution (Supplementary  Table 2 and Supplementary Fig. 2 ). KIR3DL1*001 clamped around the C-terminal end of the HLA-B*5701 antigen-binding cleft (Fig. 1a,  b) , forming an extensive interface (total buried surface area (BSA), 1,740 Å 2 ) that encompassed two discontinuous sites-one mediated via the D0 domain and the other via the D1-D2 domains (Figs 1c, d and 2a-d). KIR3DL1*001 adopted an elongated, zigzag conformation, with the three immunoglobulin (Ig) domains, termed D0, D1 and D2 (residues 7-98, 99-198 and 203-292, respectively) defined by the E-type Ig fold topology (Fig. 1a) . The D0 domain, a feature of the KIR3D family 6 packed against the D1 domain, the relative juxtapositioning of which (83u) is similar to that of the D1-D2 inter-domain angle (81u), which in turn is analogous to the relative orientation of D1-D2 domains (76u) found in the KIR2D receptors (root mean squared deviation (r.m.s. F   Q72  E19 G18  R17   G16   R79  E89   R83   Y84  I142  K146   S8   R145  A149  A150  R151   H32   H29   S11  F9  W13  S140  G138   F34   A167   M165   L166   S279   R277   D230  F276   S228   S227   E201   P199   E282   Y200 a, b, Orthogonal views of the complex with the KIR3DL1*001 b-strands labelled. The HLA and b 2 -microglobulin (b2m) are coloured green and cyan, respectively; D0, D1, D1-D2 loop and D2 are coloured yellow, blue, pink and orange, respectively; dashed line represents the unresolved loop between the E and F b-strands. c, d, The footprint mapped to the surface of HLA and KIR3DL1*001, respectively, with residues coloured in each case according to the interacting KIR3DL1*001 domain: D0 (yellow), D1 (blue), D1-D2 loop (pink) and D2 (orange). Residues that contact the linker and the D2 domain are coloured brown.
KIR3DL1 is 1.2 Å ) ( Supplementary Fig. 3a ) 4, 5 . Further, the positioning of the D0 domain relative to the D1 and D2 domains appears to be fixed ( Supplementary Fig. 3b, c) , thereby generating a pre-formed pHLA-binding receptor.
The D0 domain contributed 30% BSA upon complexation with ligand, being orientated almost perpendicular to the main axis of the antigen-binding cleft, extending towards, and just contacting, b2-microglobulin (Fig. 1a) . A surface-exposed aromatic cluster (Phe 9, Trp 13, His 29, Phe 34) on one face of the D0 domain ligated to loops comprising residues 14-18 and 88-92 of HLA-B*5701 ( Fig. 2a and Supplementary Table 3), both of which flexed slightly upon KIR3DL1*001 binding ( Supplementary Fig. 4) 
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. These two HLA loops exhibit very limited polymorphism among the HLA-A and HLA-B allotypes and mostly have main-chain interactions with the D0 domain, thereby indicating that the D0-HLA interactions are largely independent of sequence variation and likely to be conserved across most HLA allotypes. Lengthening or shortening the HLA-B*5701 loop (residues 14-18) markedly reduced binding to KIR3DL1*001 (Fig. 3a) . Alanine substitution of Ser 11, His 29 and particularly Phe 9 in KIR3DL1*001 impaired binding of HLA-B*5701 tetramers, further highlighting the importance of the D0 contacts (Fig. 3b) . Interestingly, the site of the D0-mediated interaction on HLA-B*5701 has not, to the best of our knowledge, been observed in any HLA-binding immune receptor/co-receptor to date, indicating a unique molecular recognition signature, in which the D0 domain acts as an 'innate sensor' of an essentially invariant region of the HLA molecule.
The D1-D2 domains converged to form a continuous binding interface with HLA-B*5701 (Fig. 1c, d ), interacting with residues from the a1-and a2-helices flanking the P8 position of the peptide. The ligandbinding site of the D1-D2 domains was relatively flat, facilitating the close positioning of HLA-B*5701, resulting in an intricate network of interactions across the interface; as such, the total BSA upon complexation at the D1-D2 interaction site was quite large (total BSA, 1,360 Å 2 ). The D1 and D2 domains contributed 600 and 760 Å 2 total BSA to the interface respectively, with the D1 domain docked above the a1-helix and contacting the peptide, whereas the D2 domain sat above the a2-helix, thereby providing immediate insight into the disparate roles that the D1 and D2 domains have in HLA-B*5701 engagement (Fig. 1c, d ). The D2 domain predominantly interacted with a region spanning residues 142-151 of HLA-B*5701 (Supplementary  Table 3 ), a region that shows limited polymorphism among HLA-B allotypes. At the core of the D2-HLA-B*5701 binding interface, two aromatic residues of KIR3DL1*001, Tyr 200 and Phe 276, converged onto the a2-helix, whereas polar interactions were located at the periphery (Fig. 2b) . A feature of this interface was the centrally located Glu 282 of KIR3DL1*001, a charged residue that abuts Leu 166 from the D1 domain, yet is stabilized by polar interactions with Tyr 200 and Ser 279 of KIR3DL1*001, Lys 146 of HLA-B*5701 and watermediated interactions with the peptide and Arg 83 (not shown) on the a1-helix (Fig. 2c) . Alanine substitution of Glu 201, Ser 227, Asp 230 or His 278, residues that were located at the exterior of the interface, had little effect on binding (Fig. 3b) . In contrast, alanine substitution of Tyr 200 or Phe 276, which formed the central aromatic cluster, or the charged residue Glu 282, abrogated tetramer binding (Fig. 3b) . Further, of the five HLA-B*5701 mutations made at the D2-HLA-B*5701 interface, three residues (Ile 142, Lys 146 and Ala 149) markedly affected the affinity of the interaction (Fig. 3a) . These three HLA-B*5701 residues interacted principally with Tyr 200 and Phe 276, further highlighting the importance of this internal core of KIR3DL1*001 residues in driving the D2-HLA-B*5701 interaction. Collectively, the D2-HLA-B*5701-binding site seems to have coevolved to form a highly complementary binding interface.
KIR3DL1 recognizes HLA class I allotypes that contain the Bw4 serological epitope spanning residues 77-83 on the a1-helix 8, 9 . 
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While the D1 domain was positioned over the Bw4 epitope making contacts with residues 79, 80 and 83, it interacted with a broader region of the a1-helix, including Gln 72, which bound to Met 165 (Fig. 2d and  Supplementary Table 3 ). In marked contrast to the D2-mediated contacts, the D1-HLA-B*5701 interface appeared to largely lack both charge and shape complementarity ( Fig. 2d and Supplementary Fig.  5 ). Among the residues within the Bw4 motif, Arg 79 formed van der Waals contacts with Ser 140 and hydrogen-bonded to the main chain of Gly 138. Nevertheless the environment of Arg 79 was suboptimal, with its side chain being in close proximity to Lys 136 and Ile 139 of KIR3DL1*001. Ile 80, a residue previously associated with KIR3DL1 reactivity 10 , formed a single van der Waals contact with Leu 166 and was positioned within a small hydrophobic cavity created by Glu 76, Arg 79 and Arg 83, a triad of HLA-B*5701 residues that leaned towards each other to form an array of salt-bridging interactions (Fig. 2d) . Further, Arg 83 from the Bw4 motif packed against and hydrogen-bonded to the main chain of His 278 (Fig. 2d) . Surprisingly, none of the five alanine mutations introduced into the D1 domain had a substantial effect on the KIR3DL1-pHLA-B*5701 interaction (Fig. 3b) . However, in contrast, mutation of the corresponding HLA-B*5701 contact residues did affect recognition, particularly the Ile80Ala and Arg83Ala mutations (Fig. 3a) . Interestingly, mutation of Ile 80 to Thr, a natural dimorphism within the Bw4 motif, resulted in a modest reduction in the affinity of the interaction with KIR3DL1*001 (Fig. 3a) . Presumably, the Ile80Ala and Ile80Thr mutations differentially disrupt the conformation of the Glu 76-Arg 79-Arg 83 triad, thereby affecting KIR3DL1 recognition. Thus, whereas KIR3DL1*001 contacted the highly polymorphic region of the HLA class I in a non-optimal manner, and the D1 residues were shown to be non-essential for this interaction, modifications within the HLA itself affected the D1-HLA-B*5701 interaction and thus could serve to finetune the specificity of the interaction. Indeed, although KIR3DL1*001 specifically binds HLA molecules that possess the Bw4 motif, it does not interact with the closely related Bw6 motif, which possesses a Gly at position 83. Accordingly our data provide a basis for understanding the importance of polymorphism at residue 83 for KIR3DL1 recognition of the Bw4 1 epitope 2 . The D1 domain interacted with the LSSPVTKSF peptide; however, the sole direct interaction between the peptide and KIR3DL1*001 was a van der Waals contact between P8-Ser (where P8 is position 8 of the peptide) and Leu 166 (Fig. 2c) . Thus, KIR3DL1*001 made limited contact with the peptide, analogous to the interactions observed between KIR2D and peptides bound to HLA-C 4, 5 , and in marked contrast to CD94-NKG2A recognition of HLA-E
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. To probe the role of peptide in the interaction, a series of peptides that were substituted at P8 were refolded with HLA-B*5701 and assessed for their impact on recognition by KIR3DL1*001. The Phe, His and Arg P8 substitutions all facilitated an interaction with KIR3DL1*001, albeit with lower affinities, suggesting that the receptor interface has some capacity to tolerate large side chains at P8, consistent with the presence of a solvent-filled cavity adjacent to the P8 position at the KIR3DL1*001-pHLA-B*5701 interface. In contrast, the Ala, Glu and Leu P8 substitutions markedly reduced the corresponding interaction affinities (Supplementary Table 1 and Supplementary Fig. 1 ), suggesting that the KIR3DL1*001 receptor can 'discriminate' between peptides. The basis for the differential effects of the P8 residue could be attributable either to direct steric hindrance/lack of complementarity between the peptide and KIR3DL1*001, or to conformational alteration of the residues within the Bw4 motif itself 12 . Collectively, our observations are consistent with previous studies 13, 14 , which demonstrated that the sequence of the bound peptide could have a profound effect on HLA recognition by KIR.
Next, we assessed the underlying HLA specificities of the KIR2DL and KIR3DL receptor families 4, 5 ( Supplementary Figs 6 and 7) . The D1-D2 domains of KIR3DL1*001 share clear sequence and structural homology with the HLA-C-reactive receptors, KIR2DL1, -2 and -3 (refs 4, 5, 15) , and there are a number of similarities in the recognition of the a2-helix by both KIR2DL1 and -2 and KIR3DL1*001 (Supplementary Fig. 7) . In contrast, the interactions between the KIR3DL1*001 and KIR2DL1 receptors and the a1-helices of their respective HLA class I ligands vary (Supplementary Fig. 6b ). These differences principally arise from the loop regions that connect the C and C9 b-strands and the E and F b-strands in the D1 domain and the F and F9 b-strands that bridge the D1 and D2 domains. For example, the CC9 loop in the KIR2DL receptors adopts a notably different conformation from that observed in KIR3DL1*001 (Supplementary Fig. 6c ). In KIR3DL1*001, this loop (137-140) is mostly flat and featureless, sitting adjacent to the a1-helical axis, forming limited contacts with HLA-B*5701. In the KIR2DL receptors, the corresponding loop region (42-45) is orientated towards the a1-helix, and contains two prominent residues that would prevent binding to HLA-B*5701 owing to steric hindrance with residues within the Bw4 motif. Thus, the D1-mediated contacts are critical for the HLA specificity differences between the KIR2DL1 family and KIR3DL1*001.
The KIR3D family comprises the KIR3DL1/S1, KIR3DL2 and KIR3DL3 proteins 16 . More than 200 alleles within the KIR3D family have been described, with KIR3D allomorphs generally differing from each other by a limited number of amino acids 17 . Given the high sequence identity between KIR3DL1*001 and KIR3DL2, KIR3DL3 and KIR3DS1 receptors (86, 74 and 97%, respectively), the KIR3DL1*001-HLA-B*5701 structure provided a template to examine the impact of sequence variation across the entire KIR3D family and relate this to pHLA specificity. Sequence and structural analyses suggested that a 'hotspot' resided within the D1-D2 domains, comprising loops 165-167, 199-201 and 278-282, all of which converged to form an intricate bonded network that centred on Glu 282 (Fig. 4a-e) . Variation within these three loops could potentially alter the conformation of neighbouring residues within this hotspot region, thereby affecting receptor specificity.
KIR3DS1 is distinct among the KIR3D family in that it is an activating receptor. Genetic data have shown that KIR3DL1 and KIR3DS1 are allelic variants of the same gene and suggested that KIR3DS1 interacts with HLA-Bw4 molecules bearing an Ile at residue 80 (Bw41I80) 18 . However, direct evidence of an interaction between KIR3DS1 and Bw41I80 molecules is lacking 19 . Four positions that differ between KIR3DL1 and KIR3DS1 map to the KIR3DL1*001-pHLA-B*5701 interface and thus may affect the interaction (Fig. 4c) , consistent with recent observations using HLA-A24 tetramers 20, 21 . Whereas the Gly138Trp and Pro199Leu mutations had little impact on HLA-B*5701 binding, mutation of Leu 166-which is located within the hotspot-to Arg substantially diminished tetramer binding (Fig. 4f) , thereby providing a basis for why KIR3DS1 cannot bind HLA-B*5701.
The KIR3DL2 family recognizes a limited subset of HLA-A allotypes 22, 23 , with seven sequence differences that map to the hotspot region (Fig. 4d) . The introduction of these residues into KIR3DL1*001 showed that whereas the Leu166Pro, Ala167Val (Fig. 4f) and His278Ala mutations (Fig. 3b) did not impair recognition of HLA-B*5701, the Ser279Leu and Glu282Val mutations markedly reduced tetramer binding (Fig. 4f) . Removal of the charged moiety of Glu 282 would disrupt the intricate network of interactions at the KIR3DL1*001-pHLA-B*5701 interface. Whereas the Ser279Ala mutation did not abrogate HLA-B*5701 binding (Fig. 3b) , the impact of the Ser279Leu mutation was much more pronounced. This effect appears attributable to the more bulky Leu residue causing a steric clash with Arg 83, thereby suggesting a basis for the lack of reactivity of KIR3DL2 towards the Bw4 motif. Moreover, unlike HLA-B*5701 and other HLA-Bw4 allotypes, HLA-A3 and HLA-A11 possess a Gly at position 83 rather than Arg, which is a crucial determinant for KIR3DL1 recognition of the Bw4 motif 2 .
The specificity of the KIR3DL3 receptor family is undefined, and a number of differences between KIR3DL1 and -3DL3 reside within the hotspot region (Fig. 4e) . Binding experiments showed that the LETTER RESEARCH Met165Thr or Leu166Pro substitutions in KIR3DL1*001 did not affect HLA-B*5701 binding (Fig. 4f) . Further, whereas the Pro199Leu substitution had a modest impact on recognition, the Glu282Ala substitution within KIR3DL1*001 totally abrogated tetramer binding (Fig. 3b) , thereby indicating that residues 279 and 282 are critical determinants of the specificity differences between KIR3DL1 and other KIR3D family members. Surprisingly, the extensive polymorphism among the inhibitory receptors within each KIR3D family was predominantly located at sites not directly implicated in pHLA binding (Fig. 4b) . Collectively, these observations indicate that the majority of KIR3D polymorphisms within a family 24, 25 are unlikely to directly affect the affinity of the pHLA interaction per se, but rather are likely to affect pHLA binding via altering expression levels and/or the clustering of the KIR3D receptors on the cell surface, whereas sequence differences across the KIR3D family directly affect pHLA affinity and specificity. Indeed, functional studies have shown that polymorphisms in residues such as 238 that are distant from the receptor/ligand interface can affect target cell recognition by KIR3DL1
1 NK cells 26 . Collectively, our data provide a fundamental basis for understanding how a representative KIR3DL family member interacts with an HLA-B molecule that possesses the Bw4 motif. We show that the D0 domain, a feature of this family, interacts with a previously unrecognized determinant on the HLA molecule, which is highly conserved across HLA-A and HLA-B allotypes in particular. These observations indicate that the D0 domain acts as an innate HLA sensor at a site that that is not involved in either peptide or TCR binding 27 . The KIR3DL interaction sites seem to be largely conserved across the KIR3D family, with specificity differences mapping to a hotspot within the interaction interface. In contrast, the polymorphisms within individual KIR3D gene families are largely at positions that are spatially separate from the binding site, a number of which are the subject of positive selection 17 . This suggests that other evolutionary pressures, such as pathogen-mediated immune evasion strategies, may drive KIR3D diversification at sites distant from the ligand-binding site.
METHODS SUMMARY
Protein expression and purification. Inclusion body preparations of the HLA-B*5701 heavy chain and b 2 -microglobulin were refolded and purified as detailed previously 7 . Residues 1-299 of KIR3DL1*001 were cloned into the pHLsec mammalian expression vector 28 with N-terminal 63His and secretion tags. KIR3DL1*001 was expressed from transiently transfected HEK 293S cells. Purified KIR3DL1*001 was then concentrated to 15 mg ml 21 and deglycosylated with endoglycosidase H (New England Biolabs). Crystallization and data collection. The KIR3DL1*001-pHLA-B*5701 complex was crystallized and its structure determined. Further details are provided in Methods. Transfection studies. The sequence for a Flag tag (GACTACAAAGACGATGA CGACAAG) was added to the 59 end of KIR3DL1*001 by primer addition and this cDNA was then cloned into a pEF6 vector. Specific nucleotide residues were mutated using the QuikChange II Site Directed Mutagenesis Kit (Stratagene) Plasmids were transfected into HEK293T cells using the FuGene 6 transfection reagent (Roche) according to the manufacturer's instructions. After 48 h, the cells were harvested and stained with anti-Flag (clone M2, Sigma Aldrich) antibody or with tetramer for 30 min at 4 uC. The cells were then washed and analysed on a Fortessa flow cytometer (BD Biosciences). Surface plasmon resonance. Surface plasmon resonance experiments were conducted at 25 uC on a Biacore 3000 instrument using HBS buffer (10 mM HEPES-HCl (pH 7.4), 150 mM NaCl and 0.005% surfactant P20 supplied by the manufacturer). Further details are provided in Methods. K141R   K136R   T181S   T179P   I127V   A16T   H78R  P82L   H32R  R33G  R27Q   N60I   T25A   V92L   W13R   S62G   T73R   N71T   T66P   I47V   I45S   Y30S   Q56R   N36E   G76S   R75C   M38S   G52N   H51Y   H46P   I47V   I45M   F50L  T73R   R33G   H32L   E57N   H29R   R27Q   N60L   S62G   S15G   Y40S A16T  S140T   M165T  L166P   Y281H   R44G  I49E  N71T  G22Q   T66P   T181L  P19S   R20E   K141E   Q284E   N99V   H131R   V147I   M128R   I127V   I150L   G153A V154G   K156Q  A157V  Y175F  F133L  F159Y  S144L   E282A   G238A  G239E  T269N  L291P   K212T  H241G  S218N  R243L   R118T  I161M  D258N  T197V  P246T  K250R   H278A   S279L   M231I   Y229F   P199L   E201G 
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The orientation of the first HLA molecule was found and subsequently the position of the D1 and D2 domains of the KIR receptor were placed. The second complex was fitted by application of the pseudo-translation vector 0.0, 0.5, 0.5. Refinement of the model was carried out in REFMAC with strict twofold non-crystallographic symmetry (NCS) applied. Structure building proceeded with iterative rounds of manual building in COOT and refinement in REFMAC. The D0 domain of KIR3DL1*001 was manually built from the resultant electron density maps. The NCS restraints were removed for the final rounds of refinement. Solvent was added with COOT and the structure validated with MOLPROBITY 29 . The final structure comprises two KIR3DL1*001-pHLA-B*5701 complexes in the asymmetric unit, the association of which did not indicate higher-order oligomeric assemblies within the crystal lattice. The final refinement values are summarized in Supplementary Table 2 . The crystals contained two virtually indistinguishable ternary complexes within the asymmetric unit, so structural analyses were confined to one KIR3DL1*001-pHLA-B*5701 complex. Transfection studies. The sequence for a Flag tag (GACTACAAAGACGATGA CGACAAG) was added to the 59 end of KIR3DL1*001 by primer addition and this cDNA was then cloned into a pEF6 vector. Specific nucleotide residues were mutated using the QuikChange II Site Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions using PAGE-purified primers. Sequences were verified by direct sequencing. These constructs were introduced into HEK293T cells using FuGene 6 transfection reagent (Roche) according to the manufacturer's instructions. After 48 h, the cells were harvested and stained with anti-Flag (clone M2, Sigma Aldrich) antibody or with tetramer for 30 min at 4 uC. The cells were then washed and analysed on a Fortessa flow cytometer (BD Biosciences). Analysis of cell surface expression as assessed by staining with anti-Flag monoclonal antibody showed that the introduction of the mutations had no substantial effect on expression (data not shown). All transfection data are representative of two independent experiments. SPR. SPR experiments were conducted at 25 uC on a Biacore 3000 instrument using HBS buffer (10 mM HEPES-HCl (pH 7.4), 150 mM NaCl and 0.005% surfactant P20 supplied by the manufacturer). The HLA class I-specific antibody W6/32 was immobilized on a CM5 chip via amine coupling according to manufacturer's instructions. The pHLA complexes, and mutants thereof, were captured by W6/32 creating a surface density of approximately 500-1,000 resonance units. Various concentrations of KIR3DL1*001 (2.37 to 300 mM) were injected over the captured pHLA at 5 ml min
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. The final response was calculated by subtracting the response of W6/32 alone from the KIR3DL1*001-pHLA-B*5701 complex. The equilibrium data were analysed using GraphPad Prism. The shortened form of HLA-B*5701 comprised GlyGly-Gly in place of residues 14-19; in the long form of HLA-B*5701, Gly-Gly-Gly was inserted after Gly 16. For the SPR experiments, data are representative of two independent experiments with error bars representing s.e.m. of the duplicates. 
